1
|
Leane M, Pitt K, Reynolds G, Tantuccio A, Moreton C, Crean A, Kleinebudde P, Carlin B, Gamble J, Gamlen M, Stone E, Kuentz M, Gururajan B, Khimyak YZ, Van Snick B, Andersen S, Misic Z, Peter S, Sheehan S. Ten years of the manufacturing classification system: a review of literature applications and an extension of the framework to continuous manufacture. Pharm Dev Technol 2024; 29:395-414. [PMID: 38618690 DOI: 10.1080/10837450.2024.2342953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2024] [Accepted: 04/10/2024] [Indexed: 04/16/2024]
Abstract
The MCS initiative was first introduced in 2013. Since then, two MCS papers have been published: the first proposing a structured approach to consider the impact of drug substance physical properties on manufacturability and the second outlining real world examples of MCS principles. By 2023, both publications had been extensively cited by over 240 publications. This article firstly reviews this citing work and considers how the MCS concepts have been received and are being applied. Secondly, we will extend the MCS framework to continuous manufacture. The review structure follows the flow of drug product development focussing first on optimisation of API properties. The exploitation of links between API particle properties and manufacturability using large datasets seems particularly promising. Subsequently, applications of the MCS for formulation design include a detailed look at the impact of percolation threshold, the role of excipients and how other classification systems can be of assistance. The final review section focusses on manufacturing process development, covering the impact of strain rate sensitivity and modelling applications. The second part of the paper focuses on continuous processing proposing a parallel MCS framework alongside the existing batch manufacturing guidance. Specifically, we propose that continuous direct compression can accommodate a wider range of API properties compared to its batch equivalent.
Collapse
Affiliation(s)
- Michael Leane
- Drug Product Development, Bristol Myers Squibb, Moreton, UK
| | - Kendal Pitt
- Leicester School of Pharmacy, De Montfort University, Leicester, UK
| | - Gavin Reynolds
- Oral Product Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield, UK
| | - Anthony Tantuccio
- Technology Intensification, Hovione LLC, East Windsor, New Jersey, USA
| | | | - Abina Crean
- SSPC, the SFI Centre for Pharmaceutical Research, School of Pharmacy, University College Cork, Cork, Ireland
| | - Peter Kleinebudde
- Faculty of Mathematics and Natural Sciences, Institute of Pharmaceutics and Biopharmaceutics, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Brian Carlin
- Owner, Carlin Pharma Consulting, Lawrenceville, New Jersey, USA
| | - John Gamble
- Drug Product Development, Bristol Myers Squibb, Moreton, UK
| | - Michael Gamlen
- Chief Scientific Officer, Gamlen Tableting Ltd, Heanor, UK
| | - Elaine Stone
- Consultant, Stonepharma Ltd. ATIC, Loughborough, UK
| | - Martin Kuentz
- Institute for Pharma Technology, University of Applied Sciences and Arts Northwestern Switzerland, School of Life Sciences FHNW, Muttenz, Switzerland
| | - Bindhu Gururajan
- Pharmaceutical Development, Novartis Pharma AG, Basel, Switzerland
| | - Yaroslav Z Khimyak
- School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, UK
| | - Bernd Van Snick
- Oral Solids Development, Drug Product Development, JnJ Innovative Medicine, Beerse, Belgium
| | - Sune Andersen
- Oral Solids Development, Drug Product Development, JnJ Innovative Medicine, Beerse, Belgium
| | - Zdravka Misic
- Innovation Research and Development, dsm-firmenich, Kaiseraugst, Switzerland
| | - Stefanie Peter
- Research and Development Division, F. Hoffmann-La Roche AG, Basel, Switzerland
| | - Stephen Sheehan
- External Development and Manufacturing, Alkermes Pharma Ireland Limited, Dublin 4, Ireland
| |
Collapse
|
2
|
Bhalode P, Razavi SM, Tian H, Roman-Ospino A, Scicolone J, Callegari G, Dubey A, Koolivand A, Krull S, O'Connor T, Muzzio FJ, Ierapetritou MG. Statistical data treatment for residence time distribution studies in pharmaceutical manufacturing. Int J Pharm 2024; 657:124133. [PMID: 38642620 DOI: 10.1016/j.ijpharm.2024.124133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2024] [Revised: 04/13/2024] [Accepted: 04/15/2024] [Indexed: 04/22/2024]
Abstract
Residence time distribution (RTD) method has been widely used in the pharmaceutical manufacturing for understanding powder dynamics within unit operations and continuous integrated manufacturing lines. The dynamics thus captured is then used to develop predictive models for unit operations and important RTD-based applications ensuring product quality assurance. Despite thorough efforts in tracer selection, data acquisition, and calibration model development to obtain tracer concentration profiles for RTD studies, there can exist significant noise in these profiles. This noise can make it challenging to identify the underlying signal and get a representative RTD of the system under study. Such concerns have previously indicated the importance of noise handling for RTD measurements in literature. However, the literature does not provide sufficient information on noise handling or data treatment strategies for RTD studies. To this end, we investigate the impact of varying levels of noise using different tracers on measurement of RTD profile and its applications. We quantify the impact of different denoising methods (time and frequency averaging methods). Through this investigation, we see that Savitsky Golay filtering turns out to a good method for denoising RTD profiles despite varying noise levels. The investigation is performed such that the key features of the RTD profile (which are important for RTD based applications) are preserved. Subsequently, we also investigate the impact of denoising on RTD-based applications such as out-of-specification (OOS) analysis and RTD modeling. The results show that the degree of noise levels considered in this work do not significantly impact the RTD-based applications.
Collapse
Affiliation(s)
- Pooja Bhalode
- Center of Plastics Innovation, University of Delaware, DE, USA
| | - Sonia M Razavi
- Department of Chemical and Biochemical Engineering, Rutgers University, NJ, USA
| | - Huayu Tian
- Department of Chemical and Biomolecular Engineering, University of Delaware, DE, USA
| | - Andres Roman-Ospino
- Department of Chemical and Biochemical Engineering, Rutgers University, NJ, USA
| | - James Scicolone
- Department of Chemical and Biochemical Engineering, Rutgers University, NJ, USA
| | - Gerardo Callegari
- Department of Chemical and Biochemical Engineering, Rutgers University, NJ, USA
| | - Atul Dubey
- Pharmaceutical Continuous Manufacturing (PCM), United States Pharmacopeia, 12601 Twinbrook Parkway, Rockville, MD, USA
| | - Abdollah Koolivand
- Office of Pharmaceutical Quality, Center for Drug Evaluation Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Springs, MD 20993, USA
| | - Scott Krull
- Office of Pharmaceutical Quality, Center for Drug Evaluation Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Springs, MD 20993, USA
| | - Thomas O'Connor
- Office of Pharmaceutical Quality, Center for Drug Evaluation Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Springs, MD 20993, USA
| | - Fernando J Muzzio
- Department of Chemical and Biochemical Engineering, Rutgers University, NJ, USA
| | | |
Collapse
|
3
|
Macchietti L, Melucci D, Menarini L, Consoli F, Zappi A. Analytical comparison between batch and continuous direct compression processes for pharmaceutical manufacturing using an innovative UV-Vis reflectance method and chemometrics. Int J Pharm 2024; 656:124090. [PMID: 38582101 DOI: 10.1016/j.ijpharm.2024.124090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2024] [Revised: 04/03/2024] [Accepted: 04/03/2024] [Indexed: 04/08/2024]
Abstract
Advancements in industrial technologies and the application of quality by design (QbD) guidelines are shifting the attention of manufacturers towards innovative production techniques. In the pharmaceutical field, there is a significant focus on the implementation of continuous processes, in which the production stages are carried out continuously, without the need to interrupt the process and store the production intermediates, as in traditional batch production. Such innovative production techniques also require the development of proper analytical methods able to analyze the products in-line, while still being processed. The present study aims to compare a traditional batch manufacturing process with an alternative continuous one. To this end, a real pharmaceutical formulation was used, substituting the active pharmaceutical ingredient (API) with riboflavin, at the concentration of 2 %w/w. Moreover, a direct and non-destructive analytical method based on UV-Vis reflectance spectroscopy was applied for the quantification of riboflavin in the final tablets, and compared with a traditional absorbance analysis. Good results were obtained in the comparison of both the two manufacturing processes and the two analytical methods, with R2 higher than 0.9 for all the calculated calibration models and predicted riboflavin concentrations that never significantly overcame the 15 % limits recommended by the pharmacopeia. The continuous production method demonstrated to be as reliable as the batch one, allowing to save time and money in the production step. Moreover, UV-Vis reflectance was proved to be an interesting alternative to absorption spectroscopy, which, with the proper technology, could be implemented for in-line process control.
Collapse
Affiliation(s)
- Laura Macchietti
- Department of Chemistry "G. Ciamician", University of Bologna, 40126 Bologna, Italy.
| | - Dora Melucci
- Department of Chemistry "G. Ciamician", University of Bologna, 40126 Bologna, Italy.
| | | | | | - Alessandro Zappi
- Department of Chemistry "G. Ciamician", University of Bologna, 40126 Bologna, Italy.
| |
Collapse
|
4
|
Patil H, Vemula SK, Narala S, Lakkala P, Munnangi SR, Narala N, Jara MO, Williams RO, Terefe H, Repka MA. Hot-Melt Extrusion: from Theory to Application in Pharmaceutical Formulation-Where Are We Now? AAPS PharmSciTech 2024; 25:37. [PMID: 38355916 DOI: 10.1208/s12249-024-02749-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2023] [Accepted: 01/19/2024] [Indexed: 02/16/2024] Open
Abstract
Hot-melt extrusion (HME) is a globally recognized, robust, effective technology that enhances the bioavailability of poorly soluble active pharmaceutical ingredients and offers an efficient continuous manufacturing process. The twin-screw extruder (TSE) offers an extremely resourceful customizable mixer that is used for continuous compounding and granulation by using different combinations of conveying elements, kneading elements (forward and reverse configuration), and distributive mixing elements. TSE is thus efficiently utilized for dry, wet, or melt granulation not only to manufacture dosage forms such as tablets, capsules, or granule-filled sachets, but also for designing novel formulations such as dry powder inhalers, drying units for granules, nanoextrusion, 3D printing, complexation, and amorphous solid dispersions. Over the past decades, combined academic and pharmaceutical industry collaborations have driven novel innovations for HME technology, which has resulted in a substantial increase in published articles and patents. This article summarizes the challenges and models for executing HME scale-up. Additionally, it covers the benefits of continuous manufacturing, process analytical technology (PAT) considerations, and regulatory requirements. In summary, this well-designed review builds upon our earlier publication, probing deeper into the potential of twin-screw extruders (TSE) for various new applications.
Collapse
Affiliation(s)
- Hemlata Patil
- Department of Product Development, Catalent Pharma Solutions, 14 Schoolhouse Road, Somerset, New Jersey, 08873, USA
| | - Sateesh Kumar Vemula
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, Oxford, Mississippi, 38677, USA
- Department of Pharmaceutics, School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144001, India
| | - Sagar Narala
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, Oxford, Mississippi, 38677, USA
| | - Preethi Lakkala
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, Oxford, Mississippi, 38677, USA
| | - Siva Ram Munnangi
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, Oxford, Mississippi, 38677, USA
| | - Nagarjuna Narala
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, Oxford, Mississippi, 38677, USA
| | - Miguel O Jara
- Molecular Pharmaceutics and Drug Delivery Division, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, Austin, Texas, 78712, USA
| | - Robert O Williams
- Molecular Pharmaceutics and Drug Delivery Division, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, Austin, Texas, 78712, USA
| | - Hibreniguss Terefe
- Department of Product Development, Catalent Pharma Solutions, 14 Schoolhouse Road, Somerset, New Jersey, 08873, USA
| | - Michael A Repka
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, Oxford, Mississippi, 38677, USA.
- Pii Center for Pharmaceutical Technology, The University of Mississippi, University, Oxford, Mississippi, 38677, USA.
| |
Collapse
|
5
|
Nold NM, Pearson E, Heldt CL. Economic simulation of batch and continuous aqueous two-phase purification for viral products. Biotechnol Prog 2024; 40:e3397. [PMID: 37843875 DOI: 10.1002/btpr.3397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2023] [Revised: 09/07/2023] [Accepted: 09/22/2023] [Indexed: 10/17/2023]
Abstract
Vaccine manufacturing strategies that lower capital and production costs could improve vaccine access by reducing the cost per dose and encouraging localized manufacturing. Continuous processing is increasingly utilized to drive lower costs in biological manufacturing by requiring fewer capital and operating resources. Aqueous two-phase systems (ATPS) are a liquid-liquid extraction technique that enables continuous processing for viral vectors. To date, no economic comparison between viral vector purifications using traditional methods and ATPS has been published. In this work, economic simulations of traditional chromatography-based virus purification were compared to ATPS-based virus purification for the same product output in both batch and continuous modes. First, the modeling strategy was validated by re-creating a viral subunit manufacturing economic simulation. Then, ATPS capital and operating costs were compared to that of a traditional chromatography purification at multiple scales. At all scales, ATPS purification required less than 10% of the capital expenditure compared to chromatography-based purification. At an 11 kg per year production scale, the ATPS production costs were 50% less than purification with chromatography. Other chromatography configurations were explored, and may provide a production cost benefit to ATPS, but the purity and recovery were not experimentally verified. Batch and continuous ATPS were similar in capital and production costs. However, manual price adjustments suggest that continuous ATPS plant-building costs could be less than half that of batch ATPS at the 11 kg per year production scale. These simulations show the significant reduction in manufacturing costs that ATPS-based purification could deliver to the vaccine industry.
Collapse
Affiliation(s)
- Natalie M Nold
- Department of Chemical Engineering, Michigan Technological University, Houghton, Michigan, USA
- Health Research Institute, Michigan Technological University, Houghton, Michigan, USA
| | - Eric Pearson
- Department of Chemical Engineering, Michigan Technological University, Houghton, Michigan, USA
| | - Caryn L Heldt
- Department of Chemical Engineering, Michigan Technological University, Houghton, Michigan, USA
- Health Research Institute, Michigan Technological University, Houghton, Michigan, USA
| |
Collapse
|
6
|
Jones-Salkey O, Nicusan AL, Windows-Yule CRK, Ingram A, Werner D, Clifford S, Reynolds GK. Application of Positron Emission Particle Tracking (PEPT) for the evaluation of powder behaviour in an incline linear blender for Continuous Direct Compression (CDC). Int J Pharm 2023; 645:123361. [PMID: 37673280 DOI: 10.1016/j.ijpharm.2023.123361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2023] [Revised: 08/11/2023] [Accepted: 08/31/2023] [Indexed: 09/08/2023]
Abstract
Positron Emission Particle Tracking (PEPT) is a non-invasive measurement technique which offers the ability to track the motion of individual particles with high temporal and spatial resolution, and thus build up an understanding of the bulk behaviour of a system from its microscopic (particle level) dynamics. Using this measurement technique, we have developed a series of novel metrics to better understand the behaviours of powders during the steady-state operation of a continuous blender system. Results are presented concerning the response of particle motion to processing parameters (mixing blade configuration and RPM), quantifying the motion in terms of predicted mixing performance. It was found that both increasing rpm and increasing hold-up mass (by selecting fewer transport blades and more mixing blades) provided improved mixing conditions. Interestingly, under specific conditions, there is evidence of convection-like mixing occurring at the interface of the transport and mixing region. This suggests the existence of a potential 'folding region' whereby powder is transported up the barrel (and away from the powder bulk bed) before being reconstituted back into the bulk mass. The results also provide valuable experimental data for the development, calibration and validation of future Discrete Element Method (DEM) simulations.
Collapse
Affiliation(s)
- O Jones-Salkey
- School of Chemical Engineering, University of Birmingham, Edgbaston, Birmingham, UK; Oral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, UK.
| | - A L Nicusan
- School of Chemical Engineering, University of Birmingham, Edgbaston, Birmingham, UK; School of Physics and Astronomy, University of Birmingham, Edgbaston, Birmingham, UK
| | - C R K Windows-Yule
- School of Chemical Engineering, University of Birmingham, Edgbaston, Birmingham, UK; School of Physics and Astronomy, University of Birmingham, Edgbaston, Birmingham, UK
| | - A Ingram
- School of Chemical Engineering, University of Birmingham, Edgbaston, Birmingham, UK; School of Physics and Astronomy, University of Birmingham, Edgbaston, Birmingham, UK
| | - D Werner
- School of Chemical Engineering, University of Birmingham, Edgbaston, Birmingham, UK; School of Physics and Astronomy, University of Birmingham, Edgbaston, Birmingham, UK
| | - S Clifford
- Oral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, UK
| | - G K Reynolds
- Oral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, UK
| |
Collapse
|
7
|
Zakowiecki D, Richter M, Yuece C, Voelp A, Ries M, Papaioannou M, Edinger P, Hess T, Mojsiewicz-Pieńkowska K, Cal K. Towards the Continuous Manufacturing of Liquisolid Tablets Containing Simethicone and Loperamide Hydrochloride with the Use of a Twin-Screw Granulator. Pharmaceutics 2023; 15:pharmaceutics15041265. [PMID: 37111750 PMCID: PMC10142538 DOI: 10.3390/pharmaceutics15041265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2023] [Revised: 04/13/2023] [Accepted: 04/17/2023] [Indexed: 04/29/2023] Open
Abstract
Continuous manufacturing is becoming the new technological standard in the pharmaceutical industry. In this work, a twin-screw processor was employed for the continuous production of liquisolid tablets containing either simethicone or a combination of simethicone with loperamide hydrochloride. Both active ingredients present major technological challenges, as simethicone is a liquid, oily substance, and loperamide hydrochloride was used in a very small amount (0.27% w/w). Despite these difficulties, the use of porous tribasic calcium phosphate as a carrier and the adjustment of the settings of the twin-screw processor enabled the optimization of the characteristics of the liquid-loaded powders and made it possible to efficiently produce liquisolid tablets with advantages in physical and functional properties. The application of chemical imaging by means of Raman spectroscopy allowed for the visualization of differences in the distribution of individual components of the formulations. This proved to be a very effective tool for identifying the optimum technology to produce a drug product.
Collapse
Affiliation(s)
- Daniel Zakowiecki
- Chemische Fabrik Budenheim KG, Rheinstrasse 27, 55257 Budenheim, Germany
| | - Margarethe Richter
- Thermo Electron (Karlsruhe) GmbH, Pfannkuchstrasse 10-12, 76185 Karlsruhe, Germany
| | - Ceren Yuece
- Thermo Electron (Karlsruhe) GmbH, Pfannkuchstrasse 10-12, 76185 Karlsruhe, Germany
| | - Annika Voelp
- Thermo Electron (Karlsruhe) GmbH, Pfannkuchstrasse 10-12, 76185 Karlsruhe, Germany
| | - Maximilian Ries
- Thermo Fisher Scientific GmbH, Im Steingrund 4-6, 63303 Dreieich, Germany
| | - Markos Papaioannou
- Chemische Fabrik Budenheim KG, Rheinstrasse 27, 55257 Budenheim, Germany
| | - Peter Edinger
- Chemische Fabrik Budenheim KG, Rheinstrasse 27, 55257 Budenheim, Germany
| | - Tobias Hess
- Chemische Fabrik Budenheim KG, Rheinstrasse 27, 55257 Budenheim, Germany
| | - Krystyna Mojsiewicz-Pieńkowska
- Department of Physical Chemistry, Faculty of Pharmacy, Medical University of Gdansk, al. Gen. J. Hallera 107, 80-416 Gdansk, Poland
| | - Krzysztof Cal
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Medical University of Gdansk, al. Gen. J. Hallera 107, 80-416 Gdansk, Poland
| |
Collapse
|
8
|
Rosas JG, Brush P, Thompson B, Miller C, Overton P, Tugby N, Stoliarskaia D, Hurley S, Ramasamy M, Conway SL. Implementation of a fully integrated CM direct compression and coating process at a commercial pharmaceutical facility - Part 2: PAT and RTD results for normal operational conditions batches. Int J Pharm 2023; 636:122814. [PMID: 36918116 DOI: 10.1016/j.ijpharm.2023.122814] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2022] [Revised: 03/02/2023] [Accepted: 03/05/2023] [Indexed: 03/13/2023]
Abstract
This is the second of two articles detailing the continuous manufacturing (CM) development and implementation activities for an marketed product which have been realized in novel, qualified equipment, using validated control strategy elements to enable manufacture of batches under current good manufacturing practices (cGMP) and compliant with data integrity principles. Here, the application of process analytical technologies (PAT) and automation tools on batches produced under normal operational conditions is reviewed. The results from residence time distribution (RTD) models for predicting API concentration, in-line near infrared (NIR) testing of blend uniformity (BU) and at-line NIR spectroscopy analysis of core tablet concentration and tablet identity for real-time release testing (RTRT) are discussed. The influences of process equipment and design choices on NIR and RTD model variability, as well as the use of the PAT tools for monitoring the evolving properties understanding of CM process development, such as overcoming flow instabilities, is described. Results demonstrate that the RTD and NIR models developed and validated are robust to operating conditions and are critical for assuring steady state control of the continuous manufacturing process. Finally, the NIR and RTD model lifecycle, including procedures for necessary and normal model upgrades in a cGMP production environment, are presented.
Collapse
Affiliation(s)
- Juan G Rosas
- MSD, Pharmaceutical Technical Operations PAT, UK.
| | - Peter Brush
- Merck & Co. Inc, Analytical Chemistry in Development and Supply PAT, United States
| | - Bruce Thompson
- Merck & Co. Inc, Analytical Chemistry in Development and Supply PAT, United States
| | - Charles Miller
- Merck & Co. Inc, Analytical Chemistry in Development and Supply PAT, United States
| | | | - Neil Tugby
- MSD, Pharmaceutical Technical Operations, UK
| | | | - Samantha Hurley
- Merck & Co. Inc, Pharmaceutical Commercialization Technology, United States
| | - Manoharan Ramasamy
- Merck & Co. Inc, Analytical Chemistry in Development and Supply PAT, United States
| | | |
Collapse
|
9
|
Fisher AC, Liu W, Schick A, Ramanadham M, Chatterjee S, Brykman R, Lee SL, Kozlowski S, Boam AB, Tsinontides S, Kopcha M. An Audit of Pharmaceutical Continuous Manufacturing Regulatory Submissions and Outcomes in the US. Int J Pharm 2022; 622:121778. [DOI: 10.1016/j.ijpharm.2022.121778] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Revised: 04/20/2022] [Accepted: 04/24/2022] [Indexed: 10/18/2022]
|